Monica Ronzoni

Vita-Salute San Raffaele University — Italy

Medicine · Health Sciences

32h-index5.5kcitations166works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(91), Cancer Treatment and Pharmacology(33), Gastric Cancer Management and Outcomes(31), Colorectal Cancer Surgical Treatments(29), Hepatocellular Carcinoma Treatment and Prognosis(28)

Publications163 total

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
European Journal of Cancer·2025· 2 cited
Advantages of FVIII-Extended Half-Life (Turoctocog Alfa Pegol) in the Management of Cardiac Surgery in a Patient with Mild Hemophilia A: A Case Report and Literature Review
Hematology Reports·2025Open Access
Germline genomic profiling of patients with early-onset colorectal cancer
ESMO Gastrointestinal Oncology·2025Open Access
Clinical Outcomes of Cardiac Transplantation in Heart Failure Patients with Previous Mechanical Cardiocirculatory Support
Journal of Clinical Medicine·2025Open Access
Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO.
Journal of Clinical Oncology·2024· 2 cited
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only, right-sided and/or <i>RAS</i> or <i>BRAF</i> mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials.
Journal of Clinical Oncology·2024
158TiP Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant (adj) or post-adj treatment of stage III and high-risk stage II resected colon cancer patients (pts): The ERASE-CRC project by GONO
Annals of Oncology·2024Open Access
63P FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
Annals of Oncology·2024
Preoperative MRI radiomic analysis for predicting local tumor progression in colorectal liver metastases before microwave ablation
International Journal of Hyperthermia·2024· 5 citedOpen Access
2304: Adaptive RT concomitant to oxaliplatin based chemoterapy as preoperative treatment for rectal cancer
Radiotherapy and Oncology·2024
Induction chemotherapy plus concomitant oxaliplatin-based chemoradiotherapy for locally advanced rectal cancer: A real world experience at San Raffaele Hospital.
Journal of Clinical Oncology·2024· 1 cited
2352P Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Annals of Oncology·2023Open Access
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation
Journal of Clinical Oncology·2023· 31 citedOpen Access
Immunotherapy in small bowel adenocarcinoma: a potential role?
Immunological Medicine·2023· 4 citedOpen Access
P-289 Prognostic role of clinical and pathobiological factors in patients with locally advanced gastric and esophagogastric junction cancers: Potential implications in the post-operative strategy
Annals of Oncology·2023Open Access
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study
European Journal of Cancer·2023· 15 citedOpen Access
Sex-Based Difference in Gene Alterations and Biomarkers in Anal Squamous Cell Carcinoma
SSRN Electronic Journal·2023Open Access
Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study
European Radiology·2022· 9 citedOpen Access
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.
Journal of Clinical Oncology·2022· 2 cited
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
Journal for ImmunoTherapy of Cancer·2021· 44 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Sara Lonardi(30), Vittorina Zagonel(22), Alfredo Falcone(21), Fotios Loupakis(19), Chiara Cremolini(18), Alberto Zaniboni(17), Luca Boni(15), Gianluca Masi(13), Angela Buonadonna(13), Francesca Bergamo(12), Gianluca Tomasello(11), Giuseppe Tonini(11), Giuseppe Aprile(10), Vincenzo Ricci(10), Roberto Labianca(10), Cristina Granetto(9), Eliana Rulli(9), Nicoletta Pella(9), Carlotta Antoniotti(8), Giacomo Allegrini(8)